A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer.

Conclusions: Degarelix is effective in the treatment of prostate cancer. Degarelix therapy can also be safely changed to a gonadotropin releasing hormone agonist without any adverse clinical or oncological effects. PMID: 30026950 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/30026950?dopt=Abstract

Source: Clinical Prostate Cancer - July 23, 2018 Category: Cancer & Oncology Authors: Asakawa J, Iguchi T, Tamada S, Yasuda S, Ninomiya N, Kato M, Yamasaki T, Ohmachi T, Nakatani T Tags: Basic Clin Androl Source Type: research